Avidity Biosciences, Inc.

We are proud to support the #LGBTQIA+ community as pride celebrations kick off in San Diego this week. In recognition of this year’s theme, “Making History Now,” San Diego Pride will host a series of festivities from July 13-21 to encourage future generations to blaze their own trails and make their own history. Join us as we champion our local communities and beyond: https://sdpride.org/

Happy Independence Day to our friends, families, the rare disease community, and the Avidity team! #FourthofJuly

On Friday, June 28, Avidity’s Henry Nchienzia, Ph.D will present data from the Phase 1/2 EXPLORE44™ clinical trial in healthy volunteers during Parent Project Muscular Dystrophy’s 30th Annual Conference in Orlando. We are excited to support this event and look forward to engaging with families, physicians, researchers, and industry leaders as we celebrate the incredible progress we’ve made together in the #DMD community. Join us at #PPMD2024 #PPMD30 and meet the Avidity team during the resource fair: https://lnkd.in/exuJZnwq

Diversity is central to who we are at Avidity, and we're proud to foster a work environment where everyone is welcomed, accepted, and celebrated. As we recognize #PrideMonth this June, we are proud to show our support for the LGBTQ+ community and reaffirm our commitment to creating a culture of respect, equality, and inclusivity. This year’s theme “Making History Now” encourages future generations to blaze their own path and make their own history, with local festivities kicking off this July during the San Diego Pride Festival. Join us as we come together to celebrate diversity, embrace inclusion, and champion progress https://sdpride.org/

Today we join the global facioscapulohumeral muscular dystrophy (#FSHD) community in celebrating #WorldFSHDDay. FSHD is a rare, progressive, and variable hereditary muscle-weakening condition that affects approximately 16,000 to 38,000 people in the U.S. alone. This month, we had the privilege of engaging with members of the FSHD community at the FSHD Society's FSHD Connect Conference. Listening to their stories provided invaluable insights into the challenges presented by FSHD and deepened our understanding of its impact on their lives. As we continue to advance our Phase 1/2 FORTITUDE™ clinical trial, we are committed to supporting and empowering the patient community and bringing a much-needed treatment to people living with this #raredisease. See our press release: https://lnkd.in/eBWrjF_s

Join our CEO Sarah Boyce and CMO Steve Hughes on June 20 at 11:20 am ET for a #fireside chat during the Cowen RNA Summit to learn more about the exciting progress we are making with our three clinical programs for #DM1, #DMD44, and #FSHD. To view the webcast, visit: https://lnkd.in/grNtBgD

Today, Avidity’s offices will be closed in recognition of Juneteenth – or Freedom Day. It’s important for us to recognize and honor the significance of this day, especially as an organization that strives for equality and justice. We stand committed to promoting diversity, equity, and inclusion within our workplace and local communities.

As we celebrate #FathersDay, we recognize the incredible dads and father figures who embody strength and resilience while caring for their children and loved ones living with a #raredisease. To the fathers who tirelessly research treatments, build support networks, and raise awareness, your unwavering dedication epitomizes the profound impact of fatherhood. Your efforts inspire us as we work to advance research with the potential to improve the lives of people affected by rare and serious diseases. Read the stories of Karl, Brad, and Josh – fathers who serve as proud caregivers and fierce advocates for their sons: https://lnkd.in/eaHk-mpS

We are proud to support FSHD Society's FSHD CONNECT 2024 conference taking place June 15-16 in Denver, Colorado. Held every two years, CONNECT is the world's biggest networking event for FSHD, bringing together patients and families living with FSH muscular dystrophy, clinicians, and researchers for two days of discussions focused on research, drug development, clinical trials, and more. On Saturday, June 15 at 11:50am MDT, Amy Halseth, PhD, our Executive Director of Clinical Development at Avidity, will present previously reported preliminary results from the FORTITUDE™ study, a Phase 1/2 clinical trial in adults with FSHD. We look forward to sharing the continued progress from our clinical development program in FSHD with the community. For more information about the data being presented, watch a recent webinar featuring Jeffrey Statland, M.D., Professor of Neurology, University of Kansas Medical Center, and FORTITUDE™ trial investigator: https://lnkd.in/eCbZefbR Learn more about the conference at https://lnkd.in/gHK3A-WZ

We’re thrilled that Avidity was recently featured on the Nasdaq tower in NYC’s Times Square in honor of our groundbreaking data from our Phase 1/2 FORTITUDE™ trial in people living with facioscapulohumeral muscular dystrophy (FSHD). Thank you Nasdaq for this incredible recognition, as we revolutionize a new class of targeted #RNA therapeutics using our AOC platform to profoundly improve the lives of patients and families impacted by rare diseases including #FSHD, #DM1 and #DMD.